Agilent Closes $240M Acquisition of Digital Pathology Software Maker Proscia - Clinical Lab Products
Article excerpt
Highlighted: the sentence this signal was extracted from
Nov 5, 2026 | Company News, Digital Pathology | Agilent Technologies has completed its acquisition of Proscia , a provider of digital pathology software for clinical and life sciences customers. Agilent paid $240 million in cash at closing, with up to an additional $30 million payable if Proscia meets future performance milestones. Proscia is now part of Agilent's Life Sciences and Diagnostics Markets Group. "Proscia's talented team and leading vendor-agnostic digital-pathology platform enhance our ability to support customers across clinical diagnostics, biopharma, and life-sciences research," says Padraig McDonnell, president and CEO of Agilent, in a release. "Together, Agilent and Proscia are well positioned to advance AI-enabled pathology workflows, accelerate drug discovery and companion-diagnostics solutions, and create long-term value for customers and shareholders." The transaction combines Agilent's pathology instrumentation and reagents with Proscia's vendor-agnostic digital pathology platform. The platform has FDA 510(k) clearance for primary diagnosis and an established customer base. According to Agilent, Proscia's software adds a recurring-revenue business to its pathology portfolio. The company also says the platform expands its ability to support companion diagnostics development, biopharma drug discovery, and clinical pathology workflows through AI-enabled...
Keep reading with a free account
The rest of this article, and every signal for Agilent, is in your free account.
